Trial
NCT00267683
Efficacy and Safety of Insulin Aspart Versus Glibenclamide in Type 2 Diabetes
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novo Nordisk A/S
Collaborators
—
Condition
Diabetes
Intervention
insulin aspart
Why stopped
This trial was terminated due to low recruitment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-02